 |
17 Diseases |  |
11 Trials |
|
11 Trials |  |
835 News |  |
| «1234567891011» |
- ||||| Elzonris (tagraxofusp) / Menarini
Review: 👉👉👉Check out our state-of-the-art review article: Dr Danielle Hammond @LeukemiaMDA fellow MD @DanielleHammo20 & @doctorpemm || #Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm https://t.co/xVe6j74hBv || #BPDCN #CD123 {Editor: @lane_andy } #endcancer (Twitter) - Jan 17, 2021
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Phase 2 Study of Tagraxofusp Therapy for Patients with BPDCN Post‑Autologous or Post-Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2737;
P2
Key exclusions: Persistent, clinically significant non-hematologic toxicities ≥Grade 2; CNS involvement; receiving anti-cancer therapy within 14 days of first dose of study drug; uncontrolled infection; HIV/Hepatitis B and/or C; and clinically significant cardiopulmonary disease. Endpoints: Primary endpoints include safety and tolerability of tagraxofusp in patients with BPDCN post-HCT.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Phase 2 Study of Tagraxofusp Therapy for Patients with BPDCN Post‑Autologous or Post-Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2736;
P2
Key exclusions: Persistent, clinically significant non-hematologic toxicities ≥Grade 2; CNS involvement; receiving anti-cancer therapy within 14 days of first dose of study drug; uncontrolled infection; HIV/Hepatitis B and/or C; and clinically significant cardiopulmonary disease. Endpoints: Primary endpoints include safety and tolerability of tagraxofusp in patients with BPDCN post-HCT.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Phase 2 Study of Tagraxofusp Therapy for Patients with BPDCN Post‑Autologous or Post-Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2735;
P2
Key exclusions: Persistent, clinically significant non-hematologic toxicities ≥Grade 2; CNS involvement; receiving anti-cancer therapy within 14 days of first dose of study drug; uncontrolled infection; HIV/Hepatitis B and/or C; and clinically significant cardiopulmonary disease. Endpoints: Primary endpoints include safety and tolerability of tagraxofusp in patients with BPDCN post-HCT.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Phase 2 Study of Tagraxofusp Therapy for Patients with BPDCN Post‑Autologous or Post-Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2734;
P2
Key exclusions: Persistent, clinically significant non-hematologic toxicities ≥Grade 2; CNS involvement; receiving anti-cancer therapy within 14 days of first dose of study drug; uncontrolled infection; HIV/Hepatitis B and/or C; and clinically significant cardiopulmonary disease. Endpoints: Primary endpoints include safety and tolerability of tagraxofusp in patients with BPDCN post-HCT.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Phase 2 Study of Tagraxofusp Therapy for Patients with BPDCN Post‑Autologous or Post-Allogeneic Hematopoietic Cell Transplantation () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2733;
P2
Key exclusions: Persistent, clinically significant non-hematologic toxicities ≥Grade 2; CNS involvement; receiving anti-cancer therapy within 14 days of first dose of study drug; uncontrolled infection; HIV/Hepatitis B and/or C; and clinically significant cardiopulmonary disease. Endpoints: Primary endpoints include safety and tolerability of tagraxofusp in patients with BPDCN post-HCT.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Outcomes of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Who Received Hematopoietic Stem Cell Transplantation Following Remission Induction with Tagraxofusp, a Targeted Therapy Directed to CD123 () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_827;
Treatment with TAG resulted in high rates of early and durable responses in untreated BPDCN patients which, in turn, enabled 32% of patients to be bridged to SCT. Probability of survival at 24 months was 66% in patients who achieved remission induction with TAG and were bridged to SCT, suggesting that TAG prior to SCT may provide a path to a long-term disease-free interval.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Outcomes of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Who Received Hematopoietic Stem Cell Transplantation Following Remission Induction with Tagraxofusp, a Targeted Therapy Directed to CD123 () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_826;
Treatment with TAG resulted in high rates of early and durable responses in untreated BPDCN patients which, in turn, enabled 32% of patients to be bridged to SCT. Probability of survival at 24 months was 66% in patients who achieved remission induction with TAG and were bridged to SCT, suggesting that TAG prior to SCT may provide a path to a long-term disease-free interval.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Outcomes of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Who Received Hematopoietic Stem Cell Transplantation Following Remission Induction with Tagraxofusp, a Targeted Therapy Directed to CD123 () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_825;
Treatment with TAG resulted in high rates of early and durable responses in untreated BPDCN patients which, in turn, enabled 32% of patients to be bridged to SCT. Probability of survival at 24 months was 66% in patients who achieved remission induction with TAG and were bridged to SCT, suggesting that TAG prior to SCT may provide a path to a long-term disease-free interval.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Outcomes of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Who Received Hematopoietic Stem Cell Transplantation Following Remission Induction with Tagraxofusp, a Targeted Therapy Directed to CD123 () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_824;
Treatment with TAG resulted in high rates of early and durable responses in untreated BPDCN patients which, in turn, enabled 32% of patients to be bridged to SCT. Probability of survival at 24 months was 66% in patients who achieved remission induction with TAG and were bridged to SCT, suggesting that TAG prior to SCT may provide a path to a long-term disease-free interval.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Outcomes of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Who Received Hematopoietic Stem Cell Transplantation Following Remission Induction with Tagraxofusp, a Targeted Therapy Directed to CD123 () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_823;
Treatment with TAG resulted in high rates of early and durable responses in untreated BPDCN patients which, in turn, enabled 32% of patients to be bridged to SCT. Probability of survival at 24 months was 66% in patients who achieved remission induction with TAG and were bridged to SCT, suggesting that TAG prior to SCT may provide a path to a long-term disease-free interval.
- ||| Elzonris (tagraxofusp) / Menarini
Tagraxofusp in #Myelofibrosis by @doctorpemm of @MDAndersonNews: https://t.co/1LysSOFRzq @VJHemOnc @ASH_hematology #ASH20 #HemOnc #MPNsm #CaxTx #ImmunoOnc #CTSM #TrialUpdate (Twitter) - Jan 7, 2021
- | Elzonris (tagraxofusp) / Menarini
FDA event, Journal: FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. (Pubmed Central) - Dec 18, 2020
A high proportion of patients (85%) developed neutralizing anti-drug antibodies. Tagraxofusp-erzs is the first FDA-approved treatment for BPDCN.
- | Elzonris (tagraxofusp) / Menarini
Journal: Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope. (Pubmed Central) - Dec 16, 2020
Further studies are required to resolve many several unanswered questions about tagraxofusp. In this review, we will resume and discuss pharmacological characteristic of tagraxofusp, results of clinical trials leading to its approval by FDA in 2018 and future perspectives about its use in BPDCN and other hematological malignancies.
- ||||| IMGN632 / Jazz, Elzonris (tagraxofusp) / Menarini
Clinical: @doctorpemm presenting promising data showing tolerability and efficacy of IMGN632 (novel anti-CD123 ADC) in #BDPCN. Capillary leak syndrome was not observed. ORR was 29% in a heavily pre-treated pts including those failed by tagraxofusp. #ASH20 (Twitter) - Dec 5, 2020
- ||||| IMGN632 / Jazz, Elzonris (tagraxofusp) / Menarini
Clinical: @doctorpemm @LeukemiaMDA presenting exciting data for #BPDCN pts. IMGN632 with no CLS to date and 30day TRM 0%. ORR 29% and 31% with prior tagraxofusp. Breakthrough @US_FDA #ASH20 (Twitter) - Dec 5, 2020
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] A Case of a Patient with Two Rare Histiocytic Neoplasms () - Dec 2, 2020 - Abstract #ASDP2020ASDP_431;
He developed hepatosplenic progression during induction with tagraxofusp (CD123-directed therapy of IL-3 fused with truncated diphtheria toxin), with further progression on other cytotoxic and targeted therapies for BPDCN...Given the morphology, strong CD1A positivity, and lack of diffuse langerin positivity, indeterminate cell histiocytosis (indeterminate dendritic cell tumor) was favored. It is unclear whether this represents two morphologic manifestations derived from a single abnormal histiocytic precursor, or two distinct neoplastic processes, particularly given reports of low-grade B-cell lymphoma and leukemia in association with indeterminate cell histiocytosis and the distinct molecular findings.
- ||| Elzonris (tagraxofusp) / Menarini
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm . @DanielleHammo20 @doctorpemm https://t.co/7mnkudhfLj (Twitter) - Nov 22, 2020
- ||| Elzonris (tagraxofusp) / Menarini
#BPCDN , Targeted by Tagraxofusp . This is what has been published by @doctorpemm . (Twitter) - Nov 22, 2020
- ||||| Elzonris (tagraxofusp) / Menarini
Clinical: #ASH20 | A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a #CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis | #MPNSM @doctorpemm @Vikas_Gupta_1 @AYACOUB7 @JoeKhouryMD @MrinalPatnaik https://t.co/oBzkRRHkag (Twitter) - Nov 15, 2020
- ||||| Elzonris (tagraxofusp) / Menarini
Clinical, Monotherapy: Efficacy and safety of TAG monotherapy in JAKi R/R/intolerant MF patients. >> A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary MF #MPNSM @doctorpemm @MrinalPatnaik https://t.co/0669I1RbG1 (Twitter) - Nov 13, 2020
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3784;
P2
Conclusions :Interim results demonstrate clinical efficacy and safety of TAG monotherapy in JAKi relapse/refractory/intolerant MF patients, including those associated with recognized poor-risk biological and clinical features, such as monocytosis. Some patients have experienced clinical benefit, including reduction in splenomegaly and improvement in quality of life and enrollment continues.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2747;
P1/2
Conclusions Our current correlative science studies validate target specificity of tagraxofusp against MM pDCs in relapsed and refractory MM patients enrolled in a phase 1 clinical trial and support further evaluation for this novel therapeutic to improve the clinical outcome of patients with MM. Further combination studies are planned.
- GSK3326595 / GSK, Elzonris (tagraxofusp) / Menarini
[VIRTUAL] PRMT5 Inhibition Affects RNA Methylation and Is a Potential Therapeutic Target in BPDCN (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2325;
Apart from the recently approved therapy, Tagraxofusp-erzs, treatment options for BPDCN remain limited...Functionally, in vitro growth of BPDCN cells treated with the PRMT5 inhibitor GSK3326595 (GSK595) was impaired in a dose-dependent manner, with net negative cell growth observed 6 days post-treatment...In addition, we show that elevated PRMT5 is important in BPDCN and its inhibition mitigates BPDCN progression. Therefore, PRMT5 inhibition is a potential therapeutic strategy for BPDCN.
- IMGN632 / Jazz
[VIRTUAL] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (Channel 12 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1497;
In heavily pretreated R/R BPDCN patients, including patients who had progressed following tagraxofusp, intense chemotherapies and transplant, IMGN632 demonstrated a 30% (n=7) ORR, with 4 CR/CRc responses with notable DORs. In addition, IMGN632 demonstrated a favorable safety profile that included limited grade 3+ TEAEs/SAEs, no cases of CLS, and no deaths.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_771;
In a multivariate Cox model (adjusting for age, front-line therapy, gender, and transplant) allo-SCT was significant factor for OS (HR=0.137, 95%CI=0.020-0.959, P=0.045). In conclusion, our study supports current recommendations of using SL-401 or hyper-CVAD as the first-line treatments followed by consolidation with allo-SCT in the eligible responders to induction therapy to further improve survival outcomes in BPDCN patients.
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Phase 2 Study of Tagraxofusp Therapy for BPDCN Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_760;
P2
Key exclusions: Persistent clinically significant non-hematologic toxicities ≥ grade 2; CNS involvement; receiving chemotherapy, radiotherapy, or other anti-cancer therapy within 14 days of first dose of study drug; uncontrolled infection; HIV/Hepatitis B and/or C; and clinically significant cardiopulmonary disease. Endpoints: Primary endpoints include safety and tolerability of tagraxofusp in patients with BPDCN post-HCT, with survival as secondary outcomes.
- || Elzonris (tagraxofusp) / Menarini
Biomarker, Review, Journal: CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. (Pubmed Central) - Nov 1, 2020
Multiple clinical trials are investigating the use of various CD123-targeting agents, including chimeric antigen receptor-modified T cells (expressing CD123, monoclonal antibodies, combined CD3-CD123 dual-affinity retargeting antibody therapy, recombinant fusion proteins, and CD123-engager T cells. In this review, we provide an overview of laboratory techniques used to evaluate and monitor CD123 expression, describe the strengths and limitations of detecting this biomarker in guiding therapy decisions, and provide an overview of the pharmacologic principles and strategies used in CD123-targeted therapies.
- | Elzonris (tagraxofusp) / Menarini, Nippon Shinyaku
Journal: Role of Tagraxofusp in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). (Pubmed Central) - Oct 30, 2020
In phase I/II clinical trial, major responses were observed in 90% of treatment naïve patients, with 72% of the responses observed as complete remissions. Limitations on the usage of tagraxofusp, and strategies to handle those limitations were further explored in this review.
- |||| Elzonris (tagraxofusp) / Menarini
@doctorpemm will use Tagraxofusp to treat GVHd and MRD if CD123 +. (Twitter) - Oct 11, 2020
- ||| Elzonris (tagraxofusp) / Menarini
Clinical: A good case for a combinaison: Tagraxofusp and HMA. (Twitter) - Oct 6, 2020
- |||| Elzonris (tagraxofusp) / Menarini
Approval of #tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm | Blood Advances | American Society of Hematology https://t.co/tsLMmMtu2p @doctorpemm @mkonople @LeukemiaMDA @BloodAdvances #BPDCN #WorldRareDiseaseDay @ASH_hematology #RareDisease (Twitter) - Sep 30, 2020
- | Elzonris (tagraxofusp-erzs) / Menarini
Trial completion date, Trial initiation date, Trial primary completion date: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 17, 2020
P2, N=50, Not yet recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Limitations on the usage of tagraxofusp, and strategies to handle those limitations were further explored in this review. Trial completion date: Nov 2024 --> Apr 2025 | Initiation date: Jul 2020 --> Dec 2020 | Trial primary completion date: Nov 2022 --> Apr 2023
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML) () - Sep 14, 2020 - Abstract #SOHO2020SOHO_652;
P2
The interim results represent the clinical efficacy and safety of TAG monotherapy in a cohort of CMML patients, including patients with splenomegaly, a recognized poor prognostic factor in CMML. (NCT02268253)
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis () - Sep 14, 2020 - Abstract #SOHO2020SOHO_651;
P2
The interim results demonstrate clinical efficacy and safety of TAG monotherapy in a cohort of poor-risk MF patients, including some with associated monocytosis. (NCT02268253)
- Elzonris (tagraxofusp) / Menarini
[VIRTUAL] Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial () - Sep 14, 2020 - Abstract #SOHO2020SOHO_413;
P1/2
(NCT02268253) In the largest prospectively designed study conducted to date, TAG demonstrated robust and durable responses with a median OS of 26 months and a well-characterized safety profile including recognition for CLS.
- |||||| Elzonris (tagraxofusp) / Menarini
CONGRESS | #SOHO2020 | @lane_andy from @DanaFarber shared their work on how the expression of CD123 is maintained even after treatment with tagraxofusp. To overcome resistance to TAG, they are combining it with AZA -/+ VEN #leusm (Twitter) - Sep 9, 2020
- ||| Elzonris (tagraxofusp) / Menarini
A new article came out online this week by @rosslevinemd defining a subset of #runx1 mutated #AML patients who have neoplastic pDC expansion, associated with inferior outcomes. Tagraxofusp was effective in an animal model. Looking forward to full text! https://t.co/qiW7OwVWw1 (Twitter) - Sep 6, 2020
- ||| Elzonris (tagraxofusp) / Menarini
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm [Aug 25, 2020] @doctorpemm & Dr Marina Konopleva @BloodAdvances https://t.co/ogVvMUTBmk #leusm #BPDCN #caxtx (Twitter) - Aug 31, 2020
- || Elzonris (tagraxofusp) / Menarini
I was just going to say tagraxofusp is better or “tag” as most of us have nicknamed it. At this rate we may never untwist our tongues 🤪 (Twitter) - Aug 27, 2020
- || Elzonris (tagraxofusp) / Menarini
Sometimes you just have to shrug and hope the brand name will be pronounceable. I still call SL-401 by that name rather than tagraxofusp, in part because I don’t want the droplet spray from saying the latter to contaminate my mask 😷 😉@lane_andy (Twitter) - Aug 27, 2020
- ||| Elzonris (tagraxofusp) / Menarini
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm @BloodAdvances @doctorpemm #leusm https://t.co/WTE3h4oo9S (Twitter) - Aug 26, 2020
- ||| Elzonris (tagraxofusp) / Menarini
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm [Aug 25, 2020] @doctorpemm & Dr Marina Konopleva @BloodAdvances https://t.co/ogVvMUTBmk #leusm #BPDCN #caxtx (Twitter) - Aug 26, 2020
- ||| Elzonris (tagraxofusp) / Menarini
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm [Apr 25, 2019] @doctorpemm @lane_andy et al. @NEJM https://t.co/C1ngrvmR9S #BPDCN #caxtx (Twitter) - Aug 26, 2020
- ||| Elzonris (tagraxofusp) / Menarini
3rd Pt Death Reported in SL-401 (vs IL-3 rec CD123) BPDCN & AML Trial [Mar 15, 2017] @ASHClinicalNews https://t.co/xfAkQkfkLg #BPDCN #leusm (Twitter) - Aug 26, 2020
- || Elzonris (tagraxofusp) / Menarini
"Tagraxofusp" was too easy to pronounce, hopefully "erzs" suffix will help... nice job anyway, congrats @doctorpemm ! (Twitter) - Aug 26, 2020
- |||| Elzonris (tagraxofusp) / Menarini
👉👉👉Hot off the press Just out in @BloodAdvances Our state-of-the-art review ➡️ Approval of #tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm| https://t.co/7CB88qBiFu | @ASH_hematology @LeukemiaMDA |@doctorpemm & Dr Marina Konopleva #endcancer #leusm #BPDCN (Twitter) - Aug 26, 2020
- | Gamifant (emapalumab) / SOBI, Elzonris (tagraxofusp) / Menarini
EMA To Revisit Rejection Of Elzonris & Gamifant https://t.co/uu9v3dMLli #PinkSheet (Twitter) - Aug 19, 2020
- || Venclexta (venetoclax) / Roche, AbbVie, Elzonris (tagraxofusp) / Menarini
Review, Journal: Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). (Pubmed Central) - Aug 18, 2020
Tagraxofusp is the first CD123-targeted therapy approved as the first ever targeted treatment of BPDCN in patients aged 2 years and older...These include other CD123-targeted approaches, as well as active investigation in targets beyond CD123, such as the BCL-2 inhibitor, venetoclax...Newer targeted therapies have been recently introduced, with promising results and novel toxicities that are important to recognize and understand. Stem cell transplantation after achievement of complete remission remains the mainstay of therapy among younger/fit, eligible patients, regardless of treatment modality used.
- | Elzonris (tagraxofusp) / Menarini, Nippon Shinyaku
Review, Journal: Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights. (Pubmed Central) - Aug 15, 2020
The United States Food and Drug Administration-approval of tagraxofusp (SL-401) in December 2018 has focused attention on this leukemia frequently associated with skin involvement. Herein, we aim to: (1) review etiology; (2) summarize diagnostic criteria; and (3) discuss historic treatments and novel therapies for BPDCN.